List of Excipients in Branded Drug ADALIMUMAB-BWWD

Adalimumab-bwwd Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Adalimumab-bwwd, marketed in the United States as Hadlima by Organon and Samsung Bioepis, competes primarily through a citrate-free formulation, high-concentration presentations, delivery-device options, interchangeability, and lower net cost than Humira. Its excipient system is designed to support protein stability, reduce injection burden, and preserve usability across prefilled syringes, autoinjectors, and vials. Commercial opportunity is strongest in pharmacy substitution, payer-driven biosimilar formularies, institutional contracting, and markets where device convenience influences adherence.

What is adalimumab-bwwd and who markets it?

Adalimumab-bwwd is a biosimilar monoclonal antibody to adalimumab, the active ingredient in AbbVie’s Humira. The product is marketed as Hadlima in the United States under a collaboration between Samsung Bioepis and Organon.

Attribute	Adalimumab-bwwd
Brand	Hadlima
Active ingredient	Adalimumab-bwwd
Reference product	Humira, adalimumab
Product type	Monoclonal antibody biosimilar
FDA approval	July 2023
Interchangeability	FDA interchangeable designation applies to designated presentations
Major U.S. commercialization partner	Organon
Developer	Samsung Bioepis
Main presentations	Prefilled syringe, autoinjector, vial; low- and high-concentration formats
Therapeutic areas	Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis

The FDA approved adalimumab-bwwd under the 351(k) biosimilar pathway. The approval is based on analytical, pharmacokinetic, immunogenicity and clinical comparability to Humira rather than on a new independent clinical development program for each indication (U.S. Food and Drug Administration, 2023a).

What excipients are used in adalimumab-bwwd?

The Hadlima prescribing information identifies a formulation containing histidine, histidine hydrochloride monohydrate, polysorbate 80, sodium chloride and water for injection. The exact composition can vary by presentation and concentration, so commercial and regulatory assessments should rely on the applicable product label and manufacturing documentation.

Functional role of each excipient

Excipient	Primary formulation function	Commercial relevance
L-histidine	Buffering and pH control	Helps maintain protein stability during storage
L-histidine hydrochloride monohydrate	Complementary buffer component	Supports controlled formulation pH
Polysorbate 80	Surfactant	Reduces protein adsorption and interfacial aggregation
Sodium chloride	Tonicity adjustment	Supports injection tolerability and physiological osmolality
Water for injection	Vehicle	Sterile liquid medium for subcutaneous administration

The excipient system is relatively conventional for a liquid monoclonal-antibody product. Its value is not based on ingredient novelty. The commercial advantage comes from how the excipients support a stable, citrate-free, high-concentration product that can be delivered with a smaller injection volume.

How does the citrate-free formulation affect commercial positioning?

Citrate-free formulation is a major competitive feature in the adalimumab market. Citrate buffers have historically been associated with injection-site discomfort for some patients. Removing citrate can support patient acceptance, especially in chronic self-administered treatment.

Hadlima’s formulation strategy aligns with the market transition from older, lower-concentration adalimumab products to citrate-free and high-concentration products. The commercial implications are significant:

1. Patients may receive a smaller injection volume.
2. Providers can prescribe a product that resembles newer Humira presentations.
3. Payers can switch patients without introducing an older formulation profile.
4. Pharmacy and specialty-pharmacy substitution becomes easier when device and concentration are familiar.
5. The product can compete on both price and patient experience.

Citrate-free status does not by itself establish clinical superiority. It is a product-positioning advantage that can reduce switching friction and support retention after conversion from Humira.

What formulations are protected by adalimumab-bwwd?

Adalimumab-bwwd is protected primarily through regulatory approval, manufacturing know-how, formulation development and device-related intellectual property rather than through a publicly disclosed, standalone patent estate comparable to Humira’s former patent portfolio.

The formulation has several protectable technical dimensions:

Protein stabilization

The histidine buffer system and polysorbate 80 help control pH and limit degradation pathways associated with agitation, air-liquid interfaces and contact with container surfaces. For a subcutaneous antibody, these controls are important because aggregation, fragmentation and particulates can affect quality and immunogenicity.

High-concentration delivery

High-concentration adalimumab products require control of viscosity, protein-protein interaction, syringeability and delivery force. The excipient system must support a concentrated antibody solution without creating unacceptable injection resistance.

This creates manufacturing and process barriers even when the named excipients are widely used. The relevant know-how may include:

• Mixing order and shear exposure
• Hold times and temperature controls
• Surfactant addition
• Filtration conditions
• Container closure compatibility
• Protein concentration and fill-volume tolerances
• Device injection-force specifications
• Freeze-thaw and shipping stability

Container and device compatibility

Polysorbate 80 and concentrated antibody formulations require compatibility testing with glass syringes, polymer components, elastomers and autoinjector systems. Extractables, leachables, silicone oil, tungsten residues and subvisible particles can become important quality considerations.

The device platform may be protected separately from the drug formulation. Relevant rights can cover the prefilled syringe, autoinjector geometry, needle shield, dose delivery mechanism and human-factors design.

When did adalimumab-bwwd enter the U.S. market?

Humira’s U.S. regulatory exclusivity expired in 2022, but patent settlements with AbbVie delayed most adalimumab biosimilar launches until 2023. Adalimumab-bwwd entered the U.S. market in 2023 under the settlement framework governing Samsung Bioepis and Organon.

Milestone	Timing
Humira FDA approval	2002
Humira 12-year reference-product exclusivity	Expired in 2016
Broad U.S. biosimilar launch window under AbbVie settlements	2023
Hadlima FDA approval	July 2023
U.S. Hadlima commercial launch	2023
Interchangeability pathway	Available for qualifying presentations and approved labeling

The distinction between regulatory exclusivity and patent-based launch delay is important. Humira’s biologic exclusivity ended well before biosimilar commercialization, but AbbVie’s patent settlements controlled the practical launch schedule.

What is the Orange Book and Purple Book status of adalimumab-bwwd?

Adalimumab-bwwd is a biologic, so its principal regulatory listing is in the FDA Purple Book rather than the Orange Book. The Orange Book is used primarily for small-molecule drugs approved under the 505(b) and abbreviated new drug application pathways.

The Purple Book identifies licensed biological products and biosimilar or interchangeable relationships. It does not function as a complete public patent register for biologics.

Regulatory question	Answer
Is adalimumab-bwwd listed as an FDA biosimilar?	Yes
Is it a reference product?	No
Is it interchangeable?	FDA interchangeable status applies to designated Hadlima presentations
Is it listed in the Orange Book as a conventional generic?	No
Is it listed in the Purple Book?	Yes
Does FDA approval eliminate patent litigation risk?	No

There is no conventional ANDA Paragraph IV pathway for adalimumab-bwwd. Biosimilars use the Biologics Price Competition and Innovation Act framework, including the patent-information exchange process commonly called the “patent dance.”

Which companies are challenging Humira and competing with adalimumab-bwwd?

The U.S. adalimumab biosimilar market includes products from Amgen, Boehringer Ingelheim, Sandoz, Pfizer, Samsung Bioepis and other developers or commercial partners.

Product	Active ingredient	Developer or marketer	Commercial position
Hadlima	Adalimumab-bwwd	Samsung Bioepis / Organon	High-concentration and citrate-free competition
Amjevita	Adalimumab-atto	Amgen	First U.S. adalimumab biosimilar launch
Cyltezo	Adalimumab-adbm	Boehringer Ingelheim	Interchangeable biosimilar positioning
Hyrimoz	Adalimumab-adaz	Sandoz	Biosimilar and high-concentration competition
Abrilada	Adalimumab-afzb	Pfizer	Biosimilar and interchangeable-market participation
Yusimry	Adalimumab-aqvh	Coherus	Lower-price and specialty-pharmacy positioning
Idacio	Adalimumab-aacf	Fresenius Kabi	International and U.S. biosimilar participation
Hulio	Adalimumab-fkjp	Biocon Biologics / Viatris	International and U.S. market participation

The relevant competitive variables are no longer limited to biosimilarity. They include:

• Interchangeable designation
• High-concentration availability
• Citrate-free formulation
• Autoinjector usability
• Wholesale acquisition price
• Net price after rebates
• Specialty-pharmacy access
• Payer formulary tier
• Patient-support services
• Supply reliability
• Contracting flexibility

How strong is the adalimumab-bwwd patent estate?

The product’s patent position is best characterized as moderate and execution-dependent rather than dominated by a large publicly visible composition-of-matter estate.

Patent strengths

Adalimumab-bwwd benefits from:

• A later-generation formulation profile
• Manufacturing know-how for a concentrated antibody
• Potential device and container-closure rights
• Regulatory approval across multiple indications
• A settlement-based launch position against Humira
• Potential protection for process controls and quality attributes

Patent limitations

The product does not have the same exclusivity profile as a novel biologic. Its core active ingredient is adalimumab, an established molecule whose reference-product patent portfolio has been heavily litigated.

Potential weaknesses include:

• Limited differentiation between biosimilar formulations
• Reliance on noncomposition patents
• Substitution pressure from interchangeable competitors
• Public payer focus on net price
• Difficulty enforcing formulation claims against products using different excipient systems
• Manufacturing claims that may be challenging to detect through ordinary market analysis

The most valuable IP may be operational rather than easily visible: process parameters, analytical methods, formulation scale-up, fill-finish controls and device integration.

What patent litigation affects adalimumab-bwwd?

Adalimumab-bwwd’s U.S. launch was shaped by litigation and settlement arrangements involving AbbVie’s Humira patent estate. The major issue was timing of entry rather than whether the biosimilar could receive FDA approval.

AbbVie pursued extensive litigation against adalimumab biosimilar developers, including Samsung Bioepis and other manufacturers. Settlement agreements permitted entry before the expiration of all asserted Humira patents, subject to negotiated dates and commercial terms.

No conventional Paragraph IV litigation should be assumed for Hadlima because it is not an ANDA product. The relevant legal framework is the BPCIA, patent dance disclosures, declaratory actions, infringement litigation and settlement agreements.

A commercial diligence review should separate:

1. Humira-originator patent disputes.
2. Product-specific formulation and device patents.
3. Manufacturing-process patents.
4. Biosimilar interchangeability and substitution issues.
5. Contractual restrictions in commercialization agreements.

What licensing deals support adalimumab-bwwd?

Samsung Bioepis and Organon entered into a U.S. commercialization arrangement under which Organon markets Hadlima in the United States. Samsung Bioepis supplies the biosimilar development and manufacturing platform, while Organon contributes commercial infrastructure, payer access and specialty-pharmacy capabilities.

This arrangement has strategic value because adalimumab competition depends heavily on commercialization execution. The product must reach:

• Integrated delivery networks
• Specialty pharmacies
• Employer and government formularies
• Gastroenterology and dermatology practices
• Rheumatology clinics
• Hospital outpatient systems
• Patient-assistance channels

The agreement also reduces the need for Samsung Bioepis to build a standalone U.S. commercial organization for every specialty indication.

What commercial opportunities exist for adalimumab-bwwd?

Payer-driven switching

The largest opportunity is conversion from Humira to a lower-net-cost biosimilar. Payers can use formulary preference, step edits, prior authorization and specialty-pharmacy distribution to direct utilization.

Hadlima is better positioned when its high-concentration and citrate-free presentations allow a switch without changing the patient’s injection routine materially.

Interchangeable substitution

Interchangeability can enable pharmacy-level substitution under state law, subject to payer contracts and product availability. This expands the addressable channel beyond prescriber-led switching.

The commercial value depends on whether payers treat interchangeable products as equivalent in formularies and whether pharmacies maintain sufficient inventory.

Device-based differentiation

An autoinjector can improve ease of use for patients with arthritis, limited dexterity or injection anxiety. Device differentiation can support formulary access even when biosimilar clinical differentiation is limited.

Potential commercial programs include:

• Starter packs
• Training devices
• Nurse-led injection education
• Digital adherence support
• Simplified refill coordination
• Home-delivery specialty pharmacy
• Pediatric administration support

International expansion

Outside the United States, adalimumab-bwwd can compete in European and other biosimilar markets where tender pricing, physician confidence and hospital procurement determine uptake. The same excipient strategy can support regulatory consistency across jurisdictions, but device and labeling requirements vary.

Contract manufacturing and regional supply

High-quality biosimilar production creates opportunities for regional manufacturing, fill-finish partnerships and supply agreements. Manufacturing capacity is commercially relevant because adalimumab demand is large and payer contracts can shift volume rapidly.

What generic entry risks exist for adalimumab-bwwd?

Adalimumab-bwwd faces biosimilar competition rather than traditional generic competition. The principal risks are:

Risk	Commercial effect
Aggressive net-price discounting	Compresses margin
Multiple interchangeable biosimilars	Reduces differentiation
Payer-exclusive contracting	Can rapidly reallocate volume
Device preference	May disadvantage a product with weaker usability
Supply interruption	Causes formulary delisting or substitution
Immunogenicity or tolerability signals	Can reduce physician confidence
New Humira formulation discounts	Narrows biosimilar price advantage
Manufacturing deviation	Creates recall and supply risk
State substitution variation	Limits automatic pharmacy conversion

The most immediate risk is price erosion. The most damaging strategic risk is loss of payer access before the product achieves sufficient prescriber and patient retention.

How does adalimumab-bwwd compare with Humira?

Factor	Hadlima	Humira
Regulatory status	Biosimilar, interchangeable for designated presentations	Reference biologic
Active ingredient	Adalimumab-bwwd	Adalimumab
Clinical objective	Same approved reference-product indications where applicable	Original approved indications
Formulation positioning	Citrate-free, high-concentration options	Multiple historical and newer formulations
Price position	Intended to support lower net cost	Originator pricing with rebate defense
Patent position	Product-specific and process-related rights	Extensive legacy patent estate
Commercial strength	Biosimilar access, price and device competition	Brand familiarity, installed base and contracting
Switching pathway	Prescriber, payer or pharmacy substitution depending on status and law	Retention and rebate strategies

Humira retains advantages in physician familiarity and long-term use. Hadlima’s advantages are lower cost potential, biosimilar interchangeability and a formulation designed for current injection preferences.

What is the revenue exposure for adalimumab-bwwd?

Revenue exposure is linked to the size of the adalimumab market and the speed of U.S. biosimilar conversion. The commercial opportunity is substantial because Humira historically generated more than $20 billion in annual global revenue for AbbVie before biosimilar erosion (AbbVie, 2023).

Actual Hadlima revenue depends on:

• U.S. market share
• Average net selling price
• Organon’s payer contracts
• Interchangeable substitution
• International tender wins
• Manufacturing cost per dose
• Patient persistence
• Competition from other adalimumab biosimilars

A high-volume, low-margin model is likely. The product’s commercial value rises when excipient and device choices reduce switching resistance without materially increasing cost of goods.

Key Takeaways

• Adalimumab-bwwd is marketed as Hadlima by Organon and Samsung Bioepis.
• Its excipient system uses histidine buffering, polysorbate 80, sodium chloride and water for injection.
• The formulation strategy supports protein stability, citrate-free positioning and high-concentration delivery.
• Commercial differentiation depends more on interchangeability, device usability, supply and payer access than on novel excipients.
• Humira patent settlements controlled launch timing even after biologic exclusivity expired.
• Hadlima is listed in the FDA Purple Book, not as a conventional generic in the Orange Book.
• The product faces substantial biosimilar price and formulary competition.
• Manufacturing know-how, container compatibility and device integration may be more commercially important than named excipient patents.
• The largest opportunities are payer conversion, pharmacy substitution, specialty-pharmacy distribution and international tenders.

FAQs About Adalimumab-bwwd

Is adalimumab-bwwd citrate-free?

Yes. Hadlima is positioned as a citrate-free adalimumab biosimilar. The formulation uses a histidine-based buffer system rather than a citrate buffer.

Does adalimumab-bwwd contain polysorbate 80?

Yes. Polysorbate 80 is included as a surfactant to limit protein adsorption and aggregation during storage and administration.

Is Hadlima interchangeable with Humira?

FDA interchangeable status applies to designated Hadlima presentations. Actual pharmacy substitution depends on the approved labeling, state law, payer policy and product availability.

Does adalimumab-bwwd have a Paragraph IV patent challenge?

No conventional Paragraph IV filing applies because Hadlima is a biologic biosimilar rather than an ANDA generic. Patent disputes proceed under the BPCIA framework.

What is the main commercial advantage of adalimumab-bwwd?

Its main advantages are high-concentration and citrate-free presentations, interchangeable-market access, Organon’s commercial infrastructure and the ability to compete with Humira on net price.

References

1. AbbVie Inc. (2023). Annual report 2022. AbbVie.

2. Organon & Co. (2023). Hadlima (adalimumab-bwwd) prescribing information. Organon.

3. Samsung Bioepis. (2023). Hadlima: Adalimumab-bwwd product information and U.S. commercialization materials. Samsung Bioepis.

4. U.S. Food and Drug Administration. (2023a). FDA approves biosimilar Hadlima (adalimumab-bwwd). FDA.

5. U.S. Food and Drug Administration. (2023b). Purple Book: Database of licensed biological products. FDA.

6. U.S. Food and Drug Administration. (2023c). Interchangeable biosimilar biological products. FDA.